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Abstract
A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used
at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile. New
scientific avenues have shown that manipulating the chemical structure of the saccharide moiety of digitoxin leads
to synthetic analogs with increased cytotoxic activity. However, the anticancer mechanism of digitoxin or synthetic
analogs is still subject to study while concerns about digitoxin’s cardiotoxicity preclude its clinical application in
cancer therapeutics. This review focuses on digitoxin and its analogs, and their cytotoxicity against cancer cells.
Moreover, a new perspective on the pharmacological aspects of digitoxin and its analogs is provided to emphasize
new research directions for developing potent chemotherapeutic drugs.
Introduction
Cardiac glycosides (CGs) are a large family of chemical
compounds found in several plants and animal species [1].
Plants containing CGs were used for more than 1500
years as diuretics, emetics, abortifacients, antineoplastics,
and heart tonics [2]. In the 18th century, English physician
and scientist William Withering discovered that a patient
with congestive heart failure, “dropsy”, improved after
administering foxglove extract (Digitalis purpurea L.) [3].
Since then, many CGs have been isolated and their phar-
macological effects have been tested; subsequently, CGs
were used for treating congestive heart failure, cardiac
arrhythmias, and atrial fibrillation [4,5].
Generally, CGs share a common structural motif with a
steroidal nucleus, a sugar moiety at position 3 (C3), and a
lactone moiety at position 17 (C17) [1]. Figure 1 shows
the common structural motif of CGs. The steroidal
nucleus is the core structure of CG and is considered to
be the active pharmacophoric moiety [6]. CGs also show
an A/B and C/D cis-conformation that is different from
mineralocorticoids, glycocorticoids, or sex hormones
known to show trans-confirmation [6]. The presence of
sugars at position 3 on the steroid ring significantly
affects the pharmacological profile of each glycoside
[7,8]. Free aglycones, for instance, show faster and less
complex absorption and metabolism compared to their
glycosylated counterparts [7]. Additionally, the type of
sugar attached to the steroidal nucleus changes the
potency of CG compounds [8,9].
It is well established that CGs inhibit Na+/K+-ATPase
and increases intracellular sodium ions [10]. The Na+/
K+-ATPase is a P-type pump that actively transports
potassium ions inside and sodium ions outside cells in a
2:3 stoichiometry [11]. Such activity keeps intracellular
sodium levels low, thus initiating and sustaining ade-
quate electrochemical gradient across the plasma mem-
brane [11]. Appropriate electrochemical gradient is
essential for vital cellular processes such as ion homeos-
tasis, neuronal communication, and apoptosis [10,12].
To maintain ion homeostasis after Na+/K+-ATPase inhi-
bition by CGs, the cells have to restore intracellular
sodium concentration to their basal levels by stimulating
the Na+/Ca2+ exchange pump to extrude sodium ions
out of the cell and introduce calcium ions into the cell
[10]. This activity increases intracellular calcium ions and
results in increased cellular phenomena such as calcium
dependent signaling and myocardial contractility [5].
Cardiac glycosides and their anticancer action
A growing body of evidence suggests significant antican-
cer effects mediated by CGs. For instance, in the 8th cen-
tury, CG plant extracts were used for treating malignant
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conditions [13]. An ancient Chinese remedy that employs
an extract of Bufo bufo toad secretions contains several
CGs and is still being used today for managing cancerous
conditions [14-16]. Investigations in using CGs as antic-
ancer drugs intensified in the 1960s [17,18]. Shiratori et
al. examined the cytotoxicity of CGs in rodent cancer
models and found inhibition of in vitro proliferation at
concentrations that are relatively toxic to humans (0.1-10
μM) [17]. A series of landmark epidemiological studies
by Stenkvist et al. compared breast cancer tissue samples
from women maintained on digitalis (a CG) for cardiac
conditions to tissue samples from control patients [19].
This study found that women on digitalis therapy devel-
oped more benign forms of breast tumors when com-
pared to control patients [19-22]. Additionally, patients
on digitalis treatment showed a 9.6-time lower cancer
recurrence rate compared to control patients, 5 years
after mastectomy for primary tumor [21]. In 1984, Goldin
et al. examined 127 cancer patients treated with digitalis
[23]. While patients in the control group had 21 cancer-
related deaths, only one patient died in the digitalis
group [23]. Twenty years later using follow-up data,
Stenkvist et al. found that those patients on digitalis
treatment showed significantly lower mortality rate than
the control group [22]. Given the promising epidemiolo-
gical results and the emergence of human cancer cell
lines, several studies investigated the cytotoxic effect of
different CGs on human cancer cells. Examples of the
CGs of plant or animal origins that exhibit anticancer
effects are shown in Table 1.
Digitoxin: a well established CG
Digitoxin is one of the few CGs that have been exten-
sively studied and have a well-established clinical profile
[67,68]. Digitoxin is a cardiotonic drug with a narrow
therapeutic window; thus, toxicity is a persistent con-
cern whenever digitoxin is considered for therapy [69].
Cardiotoxicity is frequently encountered as the most sig-
nificant toxicity following digitoxin’s clinical administra-
tion [70,71]. However, digitoxin is perhaps one of the
most promising anti-cancer CGs since it shows signifi-
cant anticancer effect against several types of cancer
including lung cancer, pancreatic cancer, leukemia, and
breast cancer, all at therapeutic concentrations (see
Table 1) [18,31,58,68,72]. Moreover, digitoxin has a pro-
longed half-life [69], which can potentially contribute to
a less frequent and more stable pharmacokinetic profile
in digitoxin-treated cancer patients. Such advantages
qualify digitoxin for further laboratory investigations
and clinical trials. However, to justify the anticancer
clinical application of digitoxin, its anticancer mechan-
ism ought to be clearly understood. Also, with the per-
sistent concern about digitoxin’s cardiotoxicity, further
studies are needed to clarify the cytotoxic mechanism of
digitoxin in cancer cells.
Digitoxin and its anticancer mechanism
To understand its anticancer mechanisms, initial research
focused on the ability of digitoxin to inhibit Na+/K+-
ATPase pump at concentrations between 0.5 - 5 μM
[5,10-12,73]. Such inhibition can result in increased intra-
cellular calcium via increased Na+/Ca2+ pump activity and
subsequently induce apoptosis in cancer cells [74-76].
Figure 2A shows how inhibiting the Na+/K+-ATPase
pump causes an accumulation of intracellular sodium,
thus perturbation of cellular ion homeostasis [5,10-12].
For the cells to restore ion homeostasis, the Na+/Ca2+
exchanger needs to be activated to export excess sodium
Figure 1 Structural characteristics of CGs. The common structural motif of a CG molecule is characterized by a steroidal nucleus, a lactone
moiety at C17, and a saccharide moiety at C3 linked to the steroidal nucleus by a glycosidic linkage.
Elbaz et al. Experimental Hematology & Oncology 2012, 1:4
http://www.ehoonline.org/content/1/1/4
Page 2 of 10
to the extracellular space while importing calcium, which
in turn causes an accumulation of intracellular calcium
that mediates cellular events such as myocardial contracti-
lity, cytoskeleton remodeling, and apoptosis [5,10-12].
Interestingly, however, epidemiological studies have
shown that digitoxin inhibits cancer cell viability at nano-
molar concentrations (10-100 nM) [18,31,36,58]. This
suggests that digitoxin exhibits a different mechanism for
its anticancer effect than the one initially proposed.
In 2003, Xie et al. suggested that the signaling charac-
teristics of Na+/K+-ATPase are distinct from the ion
pumping activity [77]. It was shown that Na+/K
+-ATPase signalosome is a multiple-protein signaling
complex of 3 alpha (a) subunits and 2 beta (b) subunits
Table 1 Summary of most studied CGs and their anticancer activity
Compound Structure and Natural Origin Susceptible cancer types IC50 Range References
Bufalin • Prostate cancer (PC3, DU145, and LNCaP cells)
• Leukemia (THP1, U937, and MOLT-3 cells)
0.1-10 μM [14,15,24-28]
Cinobufagin • Prostate cancer (PC3, DU145, and LNCaP cells) 0.1-10 μM [14,15,24,25,27,28]
Digitoxin • Prostate cancer (PC3, DU145, and LNCaP cells)
• Breast cancer (MCF-7 cells)
• Renal adenocarcinoma (TK-10 cells)
• Melanoma (UACC-62 cells)
• Leukemia (K-562 cells)
• Lung (A549 cells, and NCI-H460 cells)
0.01-10 μM [9,29-40]
Digoxin • Prostate cancer (PC3, DU145, and LNCaP cells)
• Cervical cancer (Hela cells)
• Lung (A549 cells, and NCI-H460 cells)
0.1-10 μM [29-32,35,40,41]
Oleandrin • Prostate cancer (PC3, DU145, LNCaP)
• Leukemia (U-937, and HL-60 cells)
• Breast cancer (MCF-7)
• Lung
• Malignant Fibroblast (VA-13)
• Liver carcinoma (HepG2 cells)
• Pancreatic cancer (PANC-1 cells)
0.1 - 1 μM [42-57]
Ouabain • Prostate cancer (PC3, DU145, LNCaP)
• Breast cancer (MDA-MB-435scells)
• Lung (NCI-H460 cells)
0.1-10 μM [2,29,30,32-35,40,46,58-62]
Proscillaridin • Breast cancer (MCF-7 cells)
• Fibroblasts
30-100 nM [29,30,32,33,35,43,63-66]
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that controls cellular activities like apoptosis [78], cell
proliferation [79], cell motility [80], and tight junctions
[81]. Subsequently, it was proposed that digitoxin at
nanomolar concentrations activates Na+/K+ATPase sig-
nalosome to transmit intracellular signals. Figure 2B
summarizes the intracellular effects of digitoxin upon
binding to Na+/K+-ATPase at concentrations between
10-100 nM. Upon binding, digitoxin modulates the Na
+/K+-ATPase protein complex activating the associated
downstream signaling pathways, i.e., activation of several
signaling cascades such as phospholipase C (PLC) sig-
naling, mitogen-activated protein kinase (MAPK) signal-
ing, phosphatidyl-inositol-3-kinase (PI3K) signaling, and
Src kinase signaling.
The signaling cascades that are stimulated upon the
interaction of digitoxin with Na+/K+-ATPase have mixed
functions. For example, the MAPK signaling is mainly a
proliferative and pro-survival signaling that can also be
complemented by a pro-apoptotic signaling capability
[82-88]. Src kinase signaling is a non-receptor tyrosine
kinase that exhibits pro-survival as well as pro-apoptotic
functions [89-97]. Therefore, digitoxin’s ability to affect
the downstream Na+/K+-ATPase signalosome is very
complex. Such complexity, together with the digitoxin’s
narrow therapeutic window and its known cardiotoxicity,
led to a slow progress in developing digitoxin as antican-
cer therapeutics [1,2,18,98].
Designing digitoxin analogs as anticancer agents
Early on, it was suggested that a potential approach to cir-
cumvent digitoxin’s cardiotoxicity is to design synthetic
analogs that are either more effective or less toxic than
digitoxin when used as anticancer agents [8,99]. Such ana-
logs were designed by structural modifications of digitox-
in’s chemical entity. For example, using digitoxin as a
template, Langenhan et al. developed MeON-neoglycosyla-
tion, a chemoselective method for glycorandomization that
employs modifying the glycosidic bond that links the sac-
charide moiety to the core steroidal nucleus of digitoxin
[99]. In 2008, Zhou and O’Doherty developed another
method for modifying the glycosidic linkage of digitoxin
using palladium-catalyzed glycosylation [100,101]. The
O’Doherty analogs are characterized by an ether linkage
between the saccharide moiety and the steroidal nucleus.
Figure 2 Effects of digitoxin on Na+/K+-ATPase at micromolar and nanomolar concentrations. (A) Old theory model summarizes the effect
of digitoxin at 0.5-5 μM concentrations. (B) New theory model summarizes digitoxin’s effect at 0.01-0.1 μM concentrations.
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As a result, novel synthetic digitoxin O-glycoside analogs
were synthesized [9,100,101]. Figure 3 shows the core
structures of digitoxin analogs synthesized by Langenhan
et al. and O’Doherty et al. respectively [99-101].
The differential potency and cytotoxic selectivity of
digitoxin MeON-neoglycosides and digitoxin O-glyco-
sides have been demonstrated in various cancer cell
lines. For instance, Iyer et al. compared a library of digi-
toxin MeON-neoglycosides and digitoxin O-glycosides
in a panel of 60 different cancer cell lines [9]. They
showed that O-glycosides are more potent anticancer
agents when compared to MeON-neoglycosides in a
variety of cancer cell lines from leukemia, to lung, pan-
creatic and breast cancer cells. Additionally, the authors
also show that the potency of the analogs depends on
their sugar moiety with the monosaccharide analog
being more potent than the di- and tri-saccharide ana-
logs, respectively. Wang et al. used artificial O-monosac-
charide analogs that they tested against a panel of 60
different cancer cell lines [37-39]. They identified three
digitoxin monosaccharide analogs that showed signifi-
cantly greater cytotoxic potential against non-small cell
lung cancer (NSCLC) cells [37-39]. The most promising
of these analogs, D6-MA, was subsequently evaluated
for its anticancer mechanism by Elbaz et al. [36].
Anticancer mechanism and selectivity of digitoxin
and D6-MA analog
Elbaz et al. showed that the D6-MA analog was 4-5
folds more potent than digitoxin in inhibiting cell prolif-
eration, inducing cell cycle arrest and apoptosis in
NSCLC cells [36]. The authors also showed that
digitoxin and D6-MA exhibited significantly greater
cytotoxicity against NSCLC when compared to both pri-
mary and non-tumorigenic lung epithelial lines. The
selective cytotoxicity in lung cancer cells included G2/M
phase arrest and apoptosis [36]. Moreover, digitoxin and
D6-MA inhibited the expression of p53, cdc2, cyclin B1,
survivin, and Chk1/2, critical genes/proteins for cell
proliferation.
In order to explain the observed anticancer effect, it is
postulated that digitoxin and D6-MA activate several
transcriptional regulatory cascades via the Na+/K
+-ATPase signalosome [61,62,77,102-107]. This sug-
gested mechanism of selective cytotoxic effect may be
associated with reduced expression of cell cycle regula-
tory proteins that are specifically overexpressed in can-
cer cells. Figure 4 illustrates how digitoxin regulates the
expression of these cancer specific proteins.
The above suggested mechanism is supported by pre-
vious work showing that digitoxin inhibits AP-1 and NF-
B signaling through the Na+/K+-ATPase signalosome
[45,55,106,108-112]. AP-1 is a transcription factor that
promotes the expression of cell cycle regulatory proteins
such as cdc2 and cyclinB1 [113-115]. Several studies have
shown that cyclinB1 is essential for cell viability [116,117].
CyclinB1 and cdc2 are overexpressed in cancer cells
[118-123] and form a complex with each other prior to
mitosis. They catalyze chromatin condensation as well as
nuclear envelope breakdown during mitosis [124,125].
The cyclinB1/cdc2 complex performs a rate limiting func-
tion in G2/M phase transition and protects mitotic cells
from apoptosis by activating survivin. Survivin is a vital
cell cycle regulatory protein known to be overexpressed in
Figure 3 The structure of novel digitoxin analogs. (A) The common structural motif of a neoglycoside molecule developed by Langenhan et
al. and characterized by a tertiary amine bond linking the saccharide moiety to the steroidal nucleus. (B) The common structural motif of a
digitoxin O-saccharide molecule developed by O’Doherty et al. and characterized by an ether bond linking the saccharide moiety to the
steroidal nucleus.
Elbaz et al. Experimental Hematology & Oncology 2012, 1:4
http://www.ehoonline.org/content/1/1/4
Page 5 of 10
different cancer types [126-131]. Survivin controls cell
progression through mitosis by promoting the chromoso-
mal passenger complex and regulating microtubule
dynamics [132-135]. Additionally, survivin regulates the
mitotic spindle checkpoint [136-139]. Several studies sug-
gest survivin downregulation as a biomarker for mitotic
catastrophe [140-142]. Also, NF-B transcription factor
regulates the expression of cell cycle regulatory proteins
such as survivin [143]. Thus, by inhibiting both AP-1 and
NF-B signaling, digitoxin and D6-MA potentially inhibit
the expression of cdc2, cyclin B1, survivin and Chk1/2, as
shown in Figures 2 and 4. Moreover, the association of
cyclin B1/cdc2 complex with survivin indicates that the
complex is crucial for G2/M phase transition and cell via-
bility, and inhibiting its expression by both digitoxin and
D6-MA could potentially explain the selective cytotoxicity
of these compounds towards cancer cells. Since inhibiting
Chk1/2 typically elicits checkpoint abrogation and uncon-
trolled cell cycle progression abolished cell viability
[144-146], a potential alternative mechanism of digitoxin
and D6-MA’s cytotoxicity may be their ability to cause
checkpoint abrogation. It is unclear, however, how digi-
toxin and D6-MA inhibit checkpoint kinase proteins in
cancer cells. Distinguishing between CG-induced cell cycle
arrest and/or checkpoint abrogation will improve our
understanding on how CGs including digitoxin and its
analogs exert their anti-proliferative/cell death effect.
Conclusions and outlook
Digitoxin and D6-MA strongly modulate cell cycle
machinery through the Na+/K+-ATPase signalosome in a
manner that significantly undermines cell viability (Figure
4). However, several questions remain unanswered regard-
ing their mechanistic control of cancer cell cycle.
Delineating the mechanism of cell cycle arrest and selec-
tivity of digitoxin and its analogs are particularly interest-
ing. First, it will improve our understanding of how
digitoxin and its analogs cause G2/M phase arrest in can-
cer cells. Second, it will help identify novel p53-indepen-
dent therapeutic targets to mediate cancer cell death.
Since many cancer types develop resistance to chemother-
apy by reducing p53 expression and signaling [158-168],
identifying p53-independent therapeutic targets will con-
tribute to the development of new and more effective can-
cer treatments by circumventing p53 related resistance
mechanisms. Third, detailing how digitoxin and D6-MA
inhibit survivin expression in cancer cells will improve our
understanding on how the drugs cause G2/M phase arrest
and apoptosis. Last, dissecting the inhibitory effects of
these compounds on survivin and p53 expression in can-
cer cells would explore whether and how the compounds
induce mitotic catastrophe. Answering these questions
will elevate our understanding on the antineoplastic
mechanism of CGs at therapeutically relevant concentra-
tions, and develop new and more effective cancer treat-
ments [147].
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